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Summary The efficacy of cyclosporin (Sandimmun") given in a daily dose of 5 mg/kg for fi weeks in severe atopic
dermatitis vi'as confirmed in this double-blind, placebo-controlied, short-term study. Of the 4f> patients
included in the study, 2 5 were randomized to receive cyclosporin and 2 J to receive placebo.
Four oftbe 2 5 patients 117%) on cyclosporin, and 14 ofthe 2 3 patients (61%) whoreceived placebo,
discontinued the trial because of inefficacy. All patients who discontinued the trial were assessed
following the principle of'intention to treat'. Compared with the baseline, the mean scores for disease
severity ffi-area, total body severity assessment ITBSA)] improved by 55%, and the mean scores for
extent of disease [rule-of-nines area assessment (KoNAAt] improved by 40%, in patients treated with
cyclosporin. Nine of the patients who received cyclosporin and completed the study (ri^ 14) had an
individual reduction of disease severity (TBSA) of 75% or more, and in three patients this reduction
was nearly 100%), ln the placebo group, a mean worsening of disease severity (4%) and of extent of the
disease (2 5%), compared with the baseline, was observed al week fi. Patients' and investigators' mean
scores for the overall efficacy were similar, and showed a statistically significant difference in favour of
cyclosporin.
Two patients on cyclosporin developed hypertension during therapy, and one of these withdrew
from the study. At the end of the trial, no .statistically significant differences in the systolic or diastolic
blood pressures were observed between the two groups. In the cyclosporin group, the increases in the
values of serum creatinine and bilirubin at week b, compared with the respective values at the
baseline, were statistically significantly different from those in the placebo group, but all values
normalized in the post-treatment period.
Cyclosporin can be a sale and very effective treatment in episodes of severe atopic dermatitis,
provided that the recommended guidelines for its administration are strictly observed.
Atopic dermatitis is a disease with a high prevalence in
the general population. It can cause affected individuals
a great deal of physical and psychological stress, and
may adversely affect work, recreation and relationships.
The accompanying pruritus also affects mood and sleep,
and thus seriously disturbs the quality of life of the
patient.' Some patients are resistant to, or develop side-
effects from, available therapies, such as topical agents
or systemic steroids. Consequently, there is a require-
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ment for an effective alternative therapy for the manage-
ment of severe atopic dermatitis.
Van loost et al. reported two patients with severe
atopic dermatitis who improved considerably within 10
days of receiving cyclosporin therapy in a dose of 5 mg/
kg/day.- The efficacy of cyclosporin in atopic dermatitis
was subsequently coniirmcd in several open studies,'"'"
and in piacebo-controlled crossover studies.' ' ' ^ Topical
application of cyclosporin in atopic dermatitis was
reported as being inctTective.''
The aim of the present multicentre, double-blind,
randomized and placebo-controlled parallel-group study
was to determine the efficacy, safety and tolerability of
cyclosporin in alopic dermatitis.
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Tahle 1, Scores ol'disease severity |6-area totitl body severity iissessmi-ni iTBSAl|. Inifiiiinn in trrm primiplc
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n = 46. Cydosporin, 2 J patients: placebo, 2 i patients, SD, standard deviation.
• Shift in the percentage (if mean values.
t P-value (not statistitaliy sisnilicantl for the tiificrence between the cyclosporin group and the placebo uroup nt week 0.
t /'-value (staliKtitally sitinificant) for the dlflerencr in the meiin shirt.s between the i-yclospurin gnmp iind ihe pliitebo group (week (V-week
Methods
Cyclosporin was administered in a dose of 5 mg/kg/duy
for fl weeks, lo patients sufferiti^ IVom .severe, long-
standing atopic dermatiti,s whieh was resistant to other
thcTJipies, and was causing the patients signilicatit
suffering and disability. Adult patietits, aged betweeti 1 7
and 68 years, who were suffering frotii severe refractory
atopic dermatitis, were enrolled in the study. At each
centre, one investigator was responsible for the clinical
assessments and recording of laboratory abnormalities.
Approval for the study was ohtained from the ethical
committees in each of the participating centres.
Infortiied consent was obtained from the patients, who
were recruited in the out-patient departments at tive
centres in the Netherlands. All patients had dermatitis
which was resistatit t(i previous therapies, including
steroid creams or ointinetits, and/or PUVA therapy,
and/or systemic steroids.
The diagnosis of atopic dermatitis was made accord-
ing to the criteria of Hanilin and Rajka." The mean
scores (and range) of disease severity and disease extent
are suiiiniariwd in Tables 1 and 2.
Patients were excluded if they had abnormal renal or
hepatic futiction, hyperkalaetnia, hypertetisioti (iticlud-
ing drug-controlled hypertension), a hi.story of malig-
nant disease, acute uncotitrolled infectiotis, epilepsy,
malabsorption syndrome, drug or alcohol abuse, and if
Table 2. Scores of disease extent (mle-of-nlnes area assessment (RoNAA)|
CycUwporin
MeantSD
Range
Placcbti
MeaniSD
Range
P-vaiue (Wilcoxon test)
n = 4fi, Cvclosporin, ' i pati
0
15-100
IX-lOO
0.7t
lents; nlacelx).
t
S2-J±2J 8
IS-IOO
2S Pittieiits. Si),
Week
2
J 6 S ± 2 2 2 1
6-100
5yS±22-9 5
27-100
5 64:21 2
i 99
H 1(1(1
4
J 4 0 ± 2 J 4
J-H7
24-100
6
J M ±26 ()
n-H7
n 100
Shift-
(week 0-week 6)
- 4 0
+ 25
0(H)09t
• Shift in the percentage of nie-in values.
t /'-value (not stutistically signiluaiil) lor ihc differenct's between the tytlitsporin group imd the plHfcbit group at week 0.
t /'-value istaListically signilitiiiiti Tor the dilVcrciKC in the mean .shifts betwet-n the lyilospodn group iinii the placcbti group (week 0-week hi.
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Cyclosporin (fi = 2 i |
MeaniSD Irange)
i'lacebo \n = 2i)
Mean + SD (range)
Age (yearsI
Raee
Sex
Duratinn of disease iyearsl
Number oi relapses l previous year!
NumbernI'motiihs free 1)1'lesiiins Ipri'vituisycarl
11 f)±12 4 (!7-fi8l
22 white Caueasiiins
1 A.sian
1 1 femalfs, 12 [nales
I 4 ± 2 ' l (O-fil
Jl-()±9-6|19-5())
22 white Caucasians
1 Asian
12 females, I 1 males
2V7± I J '2 ( l -49)
4 -5±J -3 ( ] -12 )
Table i. Admission prolile
they were taking drugs which were likely tc interfere'
with the pharmacokinetics of cyclosporin. Appropriate
contraceptive measures were imperative for women of
child-bearing age. Pregtiatit or lactating women were
excluded.'"'"' The admission prolile of ihe 4h patients
included iti this study is summarized in Table 5,
Study medication
Treatment with topical or systemic steroids or photoche-
motherapy was stopped 2 weeks before the study.
Cyclosporin or placebo were administered as coded soft
gelatine capsules of 2 5 mg and 100 mg. Patients started
on eyclosporin or placebo at a dose of S mg/kg/day. In
the event of increases in creatinine, potassium, bilirubin,
liver enzymes or blood pressure, the prescribed dose was
decreased by 25-50%,
Concomitant medication such as a systemic antihista-
tiiine (hydroxyzine 10 or 2S mg), and topical emollient
therapy (white petrolatum) was prescribed throughout
the study. However, in cases where the trial medication
was observed to be effective, the u.sc of an aniihistamine
and topical emollient was reduced or stopped as soon as
possible, depending on the clinical condition of the
patient.
Patients were to discontinue treatment prematurely
in the event of side-effects and/or poor or no response [an
improvement in h-area total body severity assessment
(TBSA} of <20%|. Patients who had either completed
the trial, or had to discontinue treatment prematurely
and hiid side-effects, were followed-up until all side-
effects had resolved. For laboratory parameters this was
defined as a return to baseline.
Clinical assessment
For clinical assessment, variables such as the severity of
the disease, lichenification, extent of the disease, itch,
loss of sleep, and global efficacy were recorded.
The severity of the disease was assessed by trained
physicians using a moditied TBSA as described pre-
viously.' ' '" Six regionfi were assessed, and included: (il
head and neck: (iil a band across the trunk defined
anatomically as lying ventrally betweeti lines joining the
apices of the atiterior axillary folds and the inguinal
ligaments and pubis, and dorsally between lities joining
the inferior borders of the scapttlae and the gluteal folds:
(iii) the hands, including the wrists (etiditig at a line
joining the lower ends of the radius and ulna): (iv) the
feet, up to lines joining the medial and lateral tnalleoli:
(v) the elbows, from niid-upper arms to mid-forearms:
(vi) the knees, from mid-thighs to mid-calves. The most
severely affected area in the speciHc region was scored.
Hach regioti was assessed for erythema, infiltration,
vesicles/papules, dryness/scaling, crackitxg/Hssuring
and excoriation/crusting, Hach sign was graded for
severity using the following scale: 0, none: I, tiiild: 2,
moderate: J, severe,
l.ichenitication was scored separately following the
same 0-3 scale, and was nt)t incorporated in the TBSA,**
The extetit of the disease was assessed using the rule-
of-nines area assessment" (RoNAA),'"' Fractions of the
individual regions (head and neck, ventral and dorsal
trunk, left and right arm, genitalia, left and right leg)
were defined in thirds. For example, the head and neck
are equal to 9%, and the area of atopic dermatitis may be
0, 5, fl or 9%. The investigator indicated the area nearest
to these four values.
At each assessment visit, itching and loss of sleep
during the previous treatment period were scored, using
the satne scale (0-i) . The overall efficacy was scored by
the patients and the investigators at week b. using the
following scaie: 0, none: 1, slight: 2, moderate; ?. good:
4, very good.
Blood pressure, haematological and biochemical pro-
files, infection, use of drugs which influence renal
function, or increase the risk of renal malfunction, were
all tnonitored as described previously,""'
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Statistics
The statistical analysis of the results hi all 4f> patients
was carried out using the SAS package (versions (vO6
and 6'{)7). All statistical tests were two-sided. A /'-valtte
of < 0 0 5 was considered as statistically significant, hi
the patients iti whom treatment wa.s stopped afler
3 weeks the results were carried forward to week 6.
The two treatment groups were cotnpared using the
Wilcoxon rank-sum test. Fisher's exact test or the chi-
squared test were used in the case of categorial results.
All patients were analysed according to the 'intetition to
treat' principle.
I'or the efficacy analysts, the baseline values of tlie
several efficacy parameters were compared in the cydo-
sporiti group and the placebo group using (he Wilcovon
rank-SLtm test, iti urder to exclude possible differetices at
week 0. The main endpoint was the TBSA. The KoNAA
was also evaluated. The relative diflerence in the
outcotTte of both assessments at week b was used in the
analysis:
100 X value at week b — value at week 0
value at week 0
The absolute difference between weeks 0 and 6 was
also used for other variables such as the total score for
lichenification, itching, loss of sleep, and the overall
efficacy of the treatment as assessed by the patient and
the investigator. The absolute difleretice was not citm-
puted for the last two variables.
Analysis of safety paratiieters (blood pressure, lieart
rate, body weight and laboratory parametersi was
performed in ihc satiie manner, i,c, the diffcretue
between the values at weeks 0 and (•> was used in the
outcome variable. Baseline values of several safety
parameters in the cyclosporin group and iti the placebo
group were compared using the VVilcoxtin ratik-sttm
test, in order to exclude possible diflerences at week 0,
Results
Fourteen patients on cyclosporin and nine oti placebo
cotTipIeted the trial \(i weeks), I'our patients on cyclo-
sporin and 14 on placebo withdrew from the study
because of lack of response to the trial medication (TBSA
reduction to baseline of <2()%). One patient on cyclo-
sporin withdrew from the study because of hypertension
which did not respottd to a reduction iti the drug dose.
Four other patients in the cyelosporin group failed lo
complete the trial because of protocol violatiotis. hi all
cases the last assessment prior to discotitinuation u as
100
80
ir 60
40
D 20
0 1 3 3 4 S 6
Weeks
rigurc 1, Scori-s ol' disease severity d-itrea, lolal (x>dy severity
asscssim-nti, mean values and standard deviations, in tho cyclosporin
and placfbu groups, *——. cydosporin: —9—. placebo.
carried forward to all subsequent visits (intention to
treat).
Meati scores of TliSA for each treattnent grottp in time
are showti in Table 1, There was a rapid decrease in the
disease severity score over the Hrst 2 weeks on cyclo-
sporin therapy, and there was a mean improvement in
disease severity score of S5% compared with baseline
after ft weeks (Table I, I ig. 1), In the placebo-treated
group, ihe mean percetitage difTerctue (week 0 vs. week
Cl) showed W{)rsening (4%). Al week fi, the diflerence
between the cyclosporin group and the placebo group,
expresseil as the meati percentage shifts from the
baseline values between the two grt)ups, was statistically
signihcatit. Nine patients iti the cyciosporin group who
completed the trial had a signiticant response of 75% or
tiiore (percetitage reduction of TliSA (o baseline), and in
three patienls in this group {n= 14) this response was
tiearly 100%, In Ihe remaining five patients who
BO
60
ai 40
20
T
X
1
1 62 3 4 S
Weeks
liptirt' 2, St'ores of disease exlent (nile-()t'-iiiin.',s jtroii a&sessmcnt),
nican values und standard dc\'iations, in the tyflosporin and placehii
groups. A- , cyclo.sporin: • - - , placebo.
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Table 4. The overall efficacy at thf end ol"cyclosporin and placebo treatment assessed by the patienls and theinvt-stiiiiitors. (Score: i), nom-; 1, slight:
2, moderate: i , good: 4. very good)
Cyciosporin (n= 19)
Assessment by the investigators
Assessment by the patients
Placebo {n-22\
Assessment by the investigators
0
"(%r
1 Ci- J)
1 (5 - J )
„ ,%)t
l4 | f i J - ( i i
I i ( T 9 - 1 \
1
« (%)*
1(15-8)
M I 5 - 8 )
„ ,%,|
1 (4-5)
J i n - 6 )
Score
2
n (%)*
2(lU-5)
J(H-S1
S(22-71
1 |4-S|
5
„
0
\
i
(%r
(2(vJ)
ilfvi)
(%)t
11 M-) 1
4
S ( 4 2 ' l l
Tiih-Hi
n l%li
219-1)
2 (9 -1 )
,Mcan score
2 - 8 ± ! - i
2 - 7 ± l - J
0-9 ± 1-J
1 •l)± 1-4
/'-value (Wilcoxon test) investigators
/'-value IWilcoxon icsti patients
n, number of patients.
* % of cyclosporin group l» = 1
t % of placebo group in = 22);
I statistically significant.
completed the study the responses were b/. 62, 5 J, JO
and 26%.
Licheniiieation improved gradually during cyclo-
sporin therapy, from a mean score of 1 ()• J at baselitie to
b-7 at week 6 I J5% improvement). Improvement in the
placebo group ranged from H}2 at entry to 8-8 at week
6 (14% improvement).
Mean scores ofthe RoNAA in each treatment group in
relntioti to time are shown in Table 2 and Figure 2. There
was a rapid improvetnent on cyciosporin during the tirst
2 weeks of treatment, and improvement continued until
the end of treatment at week b. Overall, the mean
improvement in the disease area in patients on cycio-
sporin was 40%, No improvement in disease area was
observed on piacebo. and at week 6 the disease area had
worsened by a mean of 2 5%. After 6 weeks of therapy,
the difference between the two gronps. expressed as the
mean percentage shifts of mean values, was statistically
highly significant (Table 2).
At week 6, the mean scores of itch in the cyclosporin-
treated group had improved from 2-7 to i -1, compared
with an improvement from 2-6 to 2 1 in the placebo
group. The difference between the two groups in the
improvement of itch was statistically .significant
(P = 0-011. This apparently resulted iti an itnprovement
in sleep in the cyclosporin group. The difference between
the two groups in the improvement in sleep was also
statistically significant (P-OOOl).
Twelve patients on cyclosporin (S2%) reported a total
of 28 adverse events, compared with tive patients {22%)
on placebo who reported a total of nine adverse events.
Of the 28 adverse events in patients on cyclosporin, I S
were Ihought to have a probable relationship to therapy,
and live were thought to have a definite relationship to
therapy. Three patients on cyclosporin experienced
severe adverse events (one patient had nausea, and two
developed hypertension), compared with three patients
on piacebo (one patient had pain in the legs and was
feverish, one had a swollen face and eyelids, and another
patient was dyspnoeic).
The overall efficacy at the end of treatment with
cyclosporin and placeho, as assessed by the patients and
the investigators, is shown in Table 4, Difierences
between the cyclosporin and the placebo groups were
statistically highly significant. Tolerability of cyclosporin
atid placebo was rated as good or very good by the
majority of the patients and the investigators.
At week 6, no statistically significant differences in
any of the haematological and biochemical paratneters
were observed between the cyclosporin and placebo
groups, apart from the eosinophil count (P = ()-008|.
The difference between serum creatinine values at
week 6 (mean increase i S ± i S /jmol/1) and baseline
{mean value 74-5±I2-S /nnol/l) in the cyclosporin
group, cotnpared with the difference in the placebo
group, was statistically signiiicant (P—()-()2). A decrease
in the creatinine clearance in the cyclosporin group
(mean decrease 4-2±20), compared with the baseline
[mean value 111 ± 19), was in agreement with the rise
in serum creatinine in this group. An increase in the
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liilinibin (mean iniTease i-4±5-7 ;(mol/l). but not in
lilt' other buKhemicul parameters oi liver iLinctioii. was
observed in the cyciosporin group.
Discussion
This study corroborates ihe findings of previous
studies ' ' - that short-term treatment oi severe chronic
atopic dermatitis with cyciosporin is effective and safe.
Compared with the placebo, patients on cyciosporin
showed statistically signiticant subjecllvc and objt'cti\e
improvements in disease severity score (TBSA). lichenifi-
cation score, disease extent score (RoNAA). itch, loss of
sleep and overall efticacy at the end of the h-week
treatment period, 'i'he superiority of cyciosporin over
placebo as measured by THSA and RoNAA was further
supported hy the t)verali efficacy assessments.
It is important to note that the objective clinical
features used for the assessment ofthe disease severity
(TBSA) differ from those used in olher s tudies." ' - '"
Costa I'ffi/.' assessed erythema, oedema, \esicles. crusts,
excoriations, scaling. licheniHcation. and pigmentary
changes. Olher trials have employed scores of erythema,
purnlence. excoriation or crusting, dryness or scaling,
cracking or Hssuring. and lichenification."'-^
In contrast with previous studies'' we assessed Iicheni-
lication ofthe skin, which is apparently more resistant to
short-term cyciosporin therapy."^ separately from the
disease activity (TBSA). All the different parameters were
graded separately in the most severely affected area in
the specitied region (TBSAl.
The differences in the clinical parameters contributing
to the disease severity score iTIiSA) could he an explana-
tion for discrepancies in the values for imean) clinical
improvement in the present and other studie.s.'' The use
ofthe final assessments, iollowing the intention to treat'
principle, in patients who discontinue the trial, may
influence the mean values for efficacy (at week fi) in an
unfavourable way. and this might be another explana-
tion. However. 10 patients in the cyciosporin group
(n=14). who completed the study, had a signiticant
beneficial response to this drug at week f>. The efficacy of
cyciosporin was also emphasized by the numher of
patients on placebo who withdrew from the study
{14/23 compared with 4/2 3 in the cyciosporin group).
Creatinine and bilirubiri values which were increased
on the last day ofthe trial returned to baseline within 8
weeks during the post-treatment observation period.
However, one patient, in whom the final bilirubin value
during cyciosporin therapy was slightly above normal.
could not be evaluated at follow-up. In the two patients
with liypertension. the hlood pressure returned to
normal levels during post-treatment observation.
The time to relapse of the disease could not be
determined in this study. The possibility of a rapid
relapse in severe psoriasis after withdrawal of cycio-
sporin is well documented.'^ "' In a recent randomized,
double-blind, controlled crossover study, relapse of
atopic ilermatitis was rapid after slopping cyciosporin.
but tile mean scores for disease activity and extent of
disease were less than the baseline values. However,
there was no relapse in ihe overall quality of life scores
8 weeks after cyciosporin was withdrawn.'-'
Maintenance therapy with cyciosporin for atopic
dermatitis is effective, hut controversy with regard to the
miniiiuim etfecti\ e dose, and exacerbation ofthe disease
after discontinuation of treatment." '^  suggests a need
lor further studies.
Cyciosporin has l>een shown to reduce the numbers of
helper/inducer T cells and llu- number of activated cells
expressing interleukin-2 reccplor (II,-2R ' ).''''' and these
changes correlated with a marked improvement in the
disease, supporting the view that atopic dermatitis is
based on 'I'-cell-rnediated infiammation.
Although other authors have conlirmed the relative
safety of cyciosporin in paediatric organ transplant-
ation.'" we recommend that further studies on the use of
cyciosporin in the treatment of atopic dermatitis in
children should he undertaken. Short-term treatment
with cyciosporin has bi-ndicial effects on the quality of
Hie in severe atopic dermatitis in terms of crisis interven-
t ion .""- '
In conclusion, oral cyciosporin at a dose of S mg/kg/
day lor f> weeks is an effective, safe, and well-tolernted
treatment for alopic dermatitis in adults. Cyciosporin
can signiiicantly impro\e the acute or subacute disease
severity, the extent of the disease, the lichenification.
itch, and loss of sleep. Provided that the patients are
carefully monitored according to suggested guidelines.-'
short-term (approximately 2 months) therapy wil h
cyciosporin can be saiely used during severe exacerba-
tions of atopic dermatitis.
Acknowledgments
We thank Dr ii.J.j.van l.ier (Department of Medical
Statistics, University of Nijmegen). Mr J.C.J.N.Stokvis
(Sandoz BV. the Netherlands) and Dr B.Tank (Rrasmus
University. Rotterdam) for valuable suggestitins.
640 TH.VAN]OOST('t«/.
References
1 Chimipion RH. I'iirish Wf-:. Atopjc tlcmiiiliti.s. In: TextlHMk of
Dfrmtitotogii it'hiiniplfin KH. BurliiM |t., i^ hling Flli. eds). 5th edn..
Vol, l.OxrnnirBlm-kwclIStienlituPiibiitiillons. 1992: S89-f.lO,
2 Vfin jnosi 'i'h. SIUIK i!, llfLilc !'. l'.ltii'afy of liiw-dost'cyi'i'tNP'iriitc in
.sfvtTf ylopii' skill disivisi'. .\rth ihTmiUnl \^>i7: Mi: Idfi 7.
1 l^)giiii RA. Cainp RIIK. Severe alopic LV/tma: respdnse lo (irn!
cyelosptirin A. / H SVn .\tett I'iHH: HI: 4 i r - I S .
4 Motii-y R|. WhittiikcrlA. Holt P|,\. Resolution of aUipit'ileniiHlitis
ill u palk-ru Iri-iik-d with tydosporin, tVifr I'xp Dirnuitvl I ywy; 14:
24 J-4.
=5 Taylor RS id. foopcr KD, Heiidiiinlon IT et al. C'yclosikiriric
theriipy forsi*vcrciiI(ipiLHlcniiatilis.) ,\rri .\tud ihrnuiiol I9S'>; 21:
5H(l-i.
h (rt)ld MH. Picasc-iu DI). Koenigk HH |r. Trciitment-reslNlant iitopic
dennutitis amtrollt.'d with cyclospjirin A. Int I lyernuitol 1989: 28:
4H1-2.
7 Ross JS. Citnip RDR. Cyikisporiti A in alnpii- dL-niiiflilih, lir /
Dernuttol 1990: l22(Siippl. lfil:4l i.
X .Miiiiro CS. Higyiiis \',M. Marks |M et al, Cvfltisporin A in alopii-
dermatitis: therapiLilic n-sponse is dissoiiiiu-d from efftvls on
allcrgie rciiitioiis. Hr / iVrnnif.'/ 1991: 124: 4 J-K.
*) Van |oosl Ih. Kozd MM.A. Tiiiik It cl al. L'ytlosporiiie In iitopir
dennatilis. Modulutlon in the exprt:ssion of immiinoU^k* nrnrkcrs
in lesional skin. / Am Actid Dermatul 1992; 27: 922-^«,
ID Korstanie M). Van do Slaak W)HM. L'>Tl"spiinn miiinU-nante
therapy for severe atopif dermatitis. Attii l)enn Vencret^l tStotkh)
1991:71: lSft-7.
11 Sowden IM. Iierth-|ones |, Ross j.S cl ul. Oimhlc-blind, amlrollfd.
iTOSsover sludy nf i-y<-los{Hiriii in adulls with M-VLTI' refrai-lory
atopic dermatitis, luiiitrl 1991: JJS: 1 i7-4().
12 Salek MS. I'inlay .AY. l.us<.ombi' DK ft nl. t'y(.lo.spi>rm greatly
improves the (juality of lift- of adult.s with severe utopiL dermatitis.
A randomixed. duiible-hliitd phuebo-controlled trial, lir j Derniati'l
199?: 129: 422-Ml,
1 i Ht'ule 1', l.aeijt'ndefkfr K, liin |oi)st Th. 'lopiaii fyclosporin A
Ireatnienl in psoriiisis and cilher dermatnio^iial diseases: theoreti-
ea! and prinlital aspeel.s. / liermalnl Treat 1992: 2: I 4 9 - T 5.
14 Hanitin jM. Rajka (i. Diii^nostii- features of atopii- dermatitis. Acta
Ikrm \enenvl(StiKkh> 19SU: 92(Siippl. 144): 44 7.
15 Van loost Th. Bos |D. Heute V. Meinardi MMHM. Low-dose
ryflcisporln A In severe psoriHsis. A dnuhle-Hiiid study, lir j
Dnmatol WSS: 118: IHJ-9tl,
Id lios |D, Meinardi MMHM. van Joo.st Th ft nl. Use ofcydosporin In
psoriasis./jimvi 19S9: ii: I SOU 2.
1 7 Costa C. Rillet A. \itolel M. Saurat |H. Seoring atopif dermatitis:
the simpler the belterr ,lrfn Derm Venenvl iStmkhl 19S'>: 69:
41 S.
IN SeppN.IYItsrh PO. Caneyelosporln A indiu'e permanent remission
of iitopil dermatitis; Hr I Drrmatal !99J: 128:21 ^-\^^.
19 IX' I'rost V. Miinugemeni of si-verc atopic derniiitltis. .Icdi Dirm
\'en«-r,-<>llStihkhi !992:(Suppl. I 7(i): 117 19.
20 Keowri t'.\, Urenmari 1). l.iiiidsheri; I) ct ul. I se of Lyciosp<»rin in
pedlalrk- transplantation. Immunology, pharmacology and thera-
peiillf iiiipliciitions, Clin Transpl 1991: S: IKI - i .
2 I Camp RDK. Rfitumo S. 1-rledman l'S cl ul. Cyciosporin A in severe,
therapy-rt'Sistiint atopk" dermalilis: report of an intematknial
workshop. .April 199!, lir I Dtnnawt I99J: 129:217-20.

